International Medical Case Reports Journal (Feb 2019)

Add-on administration of ultramicronized palmitoylethanolamide in the treatment of new-onset burning mouth syndrome

  • Chirchiglia D,
  • Chirchiglia P,
  • Marotta R,
  • Gallelli L

Journal volume & issue
Vol. Volume 12
pp. 39 – 42


Read online

Domenico Chirchiglia,1 Pasquale Chirchiglia,1 Rosa Marotta,2 Luca Gallelli3 1Department of Neurosurgery, University of Catanzaro, Campus Germaneto, Catanzaro 88100, Italy; 2Department of Medical-Surgical Sciences, University of Catanzaro, Campus Germaneto, Catanzaro 88100, Italy, 3Department of Pharmacology, University of Catanzaro, Campus Germaneto, Catanzaro 88100, Italy Aim: The purpose of this study was to treat burning mouth syndrome (BMS) with a combination of painful gabapentin and ultramicronized palmitoylethanolamide (umPEA), in an attempt to improve the severe symptomatology of BMS.Methods: We examined the case of a 60-year-old male, suffering from late-onset burning mouth syndrome. He found that gabapentin had a poor control of symptoms, thus we added umPEA, after administering a Visual Analog Scale (VAS), showing a score of 8–9. The patient also underwent laboratory examinations, neuroimaging exams such as brain CT/MRI and others, which all showed normal results.Results: The result of combined therapy was satisfactory. After 3 months, the frequency and intensity of the pain had improved considerably, as demonstrated clinically and by VAS, with a score of 5.Conclusion: BMS is an oral pain-burning syndrome scarcely responsive to therapy. The most widely used medications are GABA-like substances, antidepressants, topiramate. In this case, we used PEA, which proved effective in the treatment of BMS, as well as in neuropathies and migraines. Keywords: burning mouth syndrome, ultramicronized palmitoylethanolamide, gabapentin